A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up
一项针对复发/难治性多发性骨髓瘤的全人源BCMA CAR-T疗法的I期临床试验,随访时间为5年。
期刊:Blood
影响因子:23.1
doi:10.1182/blood.2024027681
Tuazon, Sherilyn A; Portuguese, Andrew J; Pont, Margot J; Cowan, Andrew J; Cole, Gabriel O; Sather, Blythe D; Song, Xiaoling; Thomas, Sushma; Wood, Brent L; Blake, Michelle; Works, Melissa G; Shadman, Mazyar; Liang, Emily C; Wu, Qian V; Voutsinas, Jenna M; Gooley, Ted A; Turtle, Cameron J; Till, Brian G; Coffey, David G; Maloney, David G; Riddell, Stanley R; Green, Damian J